PE-22-28: TREK-1 Channel Blocker Research, Neurogenesis & Antidepressant Studies

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

What Is PE-22-28?

PE-22-28 is a synthetic heptapeptide (seven amino acids) derived from spadin, a naturally occurring 17-amino-acid peptide that itself is cleaved from the propeptide of sortilin, also known as the neurotensin receptor 3 (NTSR3) precursor. Sortilin is a type I transmembrane protein widely expressed in the central nervous system, where it plays roles in protein sorting, receptor trafficking, and neurotrophin signaling. The propeptide region released during sortilin maturation was identified as a source of bioactive fragments, among which spadin attracted significant research attention for its ability to modulate potassium channel activity in neuronal tissue.

PE-22-28 represents the minimal active fragment of spadin — the shortest sequence that retains the parent peptide’s capacity to block TREK-1 (TWIK-Related Potassium Channel 1) two-pore domain potassium channels. This truncation was intentional: researchers at the Institut de Pharmacologie Moléculaire et Cellulaire (IPMC) in France systematically shortened the spadin sequence to identify the core pharmacophore responsible for TREK-1 inhibition. The result was PE-22-28, a compact peptide with improved pharmacological properties relative to the full-length spadin sequence, including enhanced metabolic stability and more consistent channel-blocking activity in electrophysiological assays.

The naming convention “PE-22-28” refers to its position within the propeptide of sortilin: it corresponds to amino acid residues 22 through 28 of that precursor sequence. This nomenclature distinguishes it from other fragments of the same propeptide that have been investigated for different biological activities.

As a research compound, PE-22-28 is supplied in lyophilized form and is typically reconstituted with bacteriostatic water for laboratory use. Its primary research interest lies in the neuroscience domain, specifically in studies investigating TREK-1 channel biology, neuronal excitability, mood-related circuitry, and hippocampal neuroplasticity.

Mechanism of Action

PE-22-28’s mechanism centers on the inhibition of TREK-1 channels, a member of the two-pore domain potassium (K2P) channel family. Understanding this mechanism requires context about TREK-1 channel biology and its role in the central nervous system.

TREK-1 Channel Biology

TREK-1 (also designated KCNK2 or K2P2.1) is a background potassium channel that contributes to the resting membrane potential of neurons. Unlike voltage-gated potassium channels that open and close in response to membrane depolarization, TREK-1 channels are constitutively active, producing a steady “leak” current that holds neurons in a hyperpolarized state. This background conductance reduces neuronal excitability — when TREK-1 channels are open and functioning normally, neurons require a larger stimulus to reach the firing threshold for action potentials.

TREK-1 channels are expressed throughout the central nervous system, with particularly high densities in the hippocampus, prefrontal cortex, amygdala, hypothalamus, and dorsal raphe nucleus — regions that collectively play central roles in mood regulation, memory formation, stress responses, and serotonergic neurotransmission. The channel is polymodal, meaning it responds to multiple types of stimuli: mechanical stretch, temperature, intracellular pH, polyunsaturated fatty acids (such as arachidonic acid), and various lipid mediators. This sensitivity to diverse inputs positions TREK-1 as an integrator of environmental and metabolic signals at the neuronal level.

The TREK-1 Knockout Evidence

The rationale for targeting TREK-1 in mood-related research emerged from a landmark observation in knockout mouse studies. TREK-1 knockout mice (TREK-1^-/-) — animals genetically engineered to lack functional TREK-1 channels — displayed a behavioral phenotype that researchers described as “antidepressant-like.” These animals showed reduced immobility in the forced swim test and tail suspension test, two widely used behavioral paradigms for screening antidepressant-like activity in rodents. Critically, the knockout mice also exhibited elevated serotonin neurotransmission in the dorsal raphe nucleus, increased efficacy of serotonergic signaling, and resistance to corticosterone-induced depression-like behavior.

This genetic evidence suggested that pharmacological blockade of TREK-1 channels might recapitulate the antidepressant-like phenotype observed in knockout animals — providing a novel, non-monoamine-reuptake-inhibitor approach to modulating mood-related circuitry. PE-22-28 was developed as a tool compound to test this hypothesis.

How PE-22-28 Blocks TREK-1

PE-22-28 acts as a direct blocker of the TREK-1 channel pore. Electrophysiological studies using patch-clamp recordings have demonstrated that PE-22-28 reduces TREK-1 currents in a concentration-dependent manner. By inhibiting this background potassium conductance, PE-22-28 shifts the resting membrane potential of TREK-1-expressing neurons toward a more depolarized state, effectively lowering the threshold for neuronal firing. In regions such as the dorsal raphe nucleus, this increased excitability of serotonergic neurons is proposed to enhance serotonin release and downstream signaling.

Importantly, PE-22-28 demonstrates selectivity for TREK-1 over other members of the K2P channel family. While no small molecule or peptide is perfectly selective, the degree of TREK-1 preference observed in electrophysiological assays suggests that PE-22-28’s effects are predominantly mediated through this specific channel subtype rather than through broad potassium channel inhibition.

Downstream Effects Observed in Preclinical Models

The downstream consequences of TREK-1 blockade by PE-22-28 have been documented across several interconnected signaling pathways in animal models:

• BDNF upregulation — Brain-derived neurotrophic factor (BDNF) is a key neurotrophin involved in neuronal survival, synaptic plasticity, and the growth of new neurons. PE-22-28 administration has been observed to increase BDNF expression in the hippocampus of rodent models. BDNF upregulation is a common feature of established antidepressant mechanisms and is considered a critical mediator of neuroplastic changes associated with mood improvement in preclinical paradigms.
• Serotonin enhancement — Consistent with the TREK-1 knockout phenotype, PE-22-28 has been shown to increase serotonergic neurotransmission. By depolarizing serotonergic neurons in the dorsal raphe nucleus, TREK-1 blockade enhances the firing rate of these neurons, leading to increased serotonin release in projection areas including the hippocampus and prefrontal cortex.
• Hippocampal neurogenesis — PE-22-28 has been reported to promote neurogenesis in the dentate gyrus of the hippocampus in rodent models. Adult hippocampal neurogenesis — the birth of new neurons from neural stem cells — has been implicated in mood regulation and cognitive function, and its stimulation is a shared property of several classes of antidepressant compounds studied in animal models.
• Rapid onset of action — One of the most notable findings in PE-22-28 research is the speed at which behavioral effects are observed. In rodent depression models, PE-22-28 has demonstrated antidepressant-like behavioral effects within approximately 4 days of administration, compared to the 3 to 4 weeks typically required for selective serotonin reuptake inhibitors (SSRIs) to produce comparable behavioral changes in the same models. This rapid onset has generated particular research interest, as the delayed therapeutic effect of conventional antidepressants remains one of the significant challenges in the field.

Research Applications

PE-22-28’s research profile spans several interconnected areas of neuroscience. The following sections describe the principal domains in which this peptide has been investigated in preclinical settings.

Antidepressant Mechanism Research

The primary research application of PE-22-28 is as a pharmacological tool for studying TREK-1 channel blockade as an antidepressant mechanism. Studies have employed PE-22-28 in the forced swim test, tail suspension test, novelty-suppressed feeding test, and chronic mild stress paradigms — all established behavioral models used to evaluate antidepressant-like activity in rodents. Across these paradigms, PE-22-28 has consistently produced behavioral changes indicative of antidepressant-like activity, supporting the hypothesis that TREK-1 blockade represents a viable target in mood-related research.

The rapid onset observed with PE-22-28 has made it a particularly valuable tool for investigating the temporal dynamics of antidepressant mechanisms. Researchers have used PE-22-28 to study what molecular and cellular events underlie rapid-acting versus delayed-acting antidepressant effects, a question with significant implications for understanding the neurobiology of depression models.

Neurogenesis and Neuroplasticity Studies

PE-22-28’s ability to promote hippocampal neurogenesis has positioned it as a research tool in the study of adult neural stem cell biology. Investigators have used PE-22-28 to examine the relationship between TREK-1 channel activity, neural progenitor cell proliferation, and the maturation and integration of newborn neurons into existing hippocampal circuits. These studies contribute to the broader understanding of how ion channel activity in the neurogenic niche regulates the birth and survival of new neurons.

BDNF upregulation by PE-22-28 is relevant to neuroplasticity research beyond neurogenesis. BDNF-TrkB signaling is central to synaptic strengthening, dendritic remodeling, and long-term potentiation — processes that underlie learning, memory, and adaptive responses to environmental challenges. PE-22-28 has been used as a tool to study BDNF-dependent plasticity in the context of TREK-1 channel modulation.

TREK-1 Channel Biology

Beyond its mood-related applications, PE-22-28 serves as a selective pharmacological probe for TREK-1 channel function. TREK-1 channels are implicated in a range of physiological processes beyond mood regulation, including nociception (pain signaling), neuroprotection during ischemia, anesthesia sensitivity, and thermoregulation. PE-22-28 enables researchers to dissect the contribution of TREK-1 to these processes with greater specificity than genetic knockout approaches, which eliminate the channel throughout development and across all tissues.

Cognitive Function Research

Given the dense expression of TREK-1 channels in the hippocampus and prefrontal cortex — brain regions essential for learning and memory — PE-22-28 has been investigated in cognitive paradigms. Preclinical studies have examined PE-22-28’s effects on spatial memory (Morris water maze), recognition memory (novel object recognition), and fear conditioning. The convergence of BDNF enhancement, neurogenesis stimulation, and increased serotonergic tone suggests that TREK-1 blockade may influence cognitive processes through multiple parallel mechanisms, though this remains an area of active investigation.

Comparison with Related Neuropeptide Research

PE-22-28 occupies a distinct niche within the broader landscape of neuropeptide research. Its mechanism of action — direct ion channel blockade — differs fundamentally from the receptor-mediated mechanisms of other neuropeptides studied for neurological research applications:

• Semax, a synthetic analog of ACTH(4-10), acts through melanocortin receptor pathways and BDNF modulation (Semax Research Guide).
• Selank, a synthetic analog of tuftsin, modulates GABAergic and monoaminergic neurotransmission (Selank Research Guide).
• P21, a synthetic peptide derived from CNTF, promotes neurogenesis through a neurotrophic mechanism distinct from ion channel modulation (P21 Research Guide).
• Cerebrolysin, a peptide mixture derived from porcine brain proteins, acts through multiple neurotrophic factor pathways (Cerebrolysin Research Guide).
• Pinealon, a short regulatory peptide (Glu-Asp-Arg), has been studied for neuroprotective properties through gene expression modulation.

This mechanistic distinction makes PE-22-28 a complementary research tool within neuroscience laboratories studying neuroprotection, mood circuitry, and neuroplasticity from different pharmacological angles.

Dosing in Preclinical Research

The following table summarizes dosing parameters that have been reported in published preclinical studies of PE-22-28 and its parent peptide spadin. These are provided as reference for the research literature and do not constitute recommendations for any application. No validated human dosing protocol exists for PE-22-28.

Parameter	Detail
Molecular classification	Synthetic heptapeptide (7 amino acids)
Parent compound	Spadin (propeptide of sortilin, residues 22-28)
Target	TREK-1 (KCNK2/K2P2.1) two-pore domain potassium channel
Preclinical species	Mice (primary), rats
Reported research doses (mice)	0.1 – 1 mg/kg, intraperitoneal or intravenous
Administration routes studied	Intraperitoneal (IP), intravenous (IV), intranasal (exploratory)
Duration in behavioral studies	Acute (single dose) and subchronic (4–7 days)
Onset of behavioral effects	~4 days in chronic mild stress models
Reconstitution	Lyophilized peptide reconstituted with bacteriostatic water
Storage (reconstituted)	2–8°C, protected from light
Human dosing data	None — no human clinical trials have been conducted

Important note on dose translation: Preclinical doses in rodents cannot be directly converted to equivalent doses in other species using simple body-weight ratios. Allometric scaling, differences in metabolic rate, blood-brain barrier permeability, peptide clearance rates, and route-specific bioavailability all affect dose translation across species. The absence of any human pharmacokinetic data for PE-22-28 means that no evidence-based dose extrapolation is currently possible.

Safety Profile

The safety profile of PE-22-28 in the published literature is limited to observations from preclinical studies. No human clinical trials have been conducted, and consequently no formal safety assessment in humans exists for this compound.

Preclinical Safety Observations

In rodent studies, PE-22-28 has generally been described as well-tolerated at the doses tested. Published studies have not reported significant adverse effects, acute toxicity, or mortality at standard experimental doses. Animals receiving PE-22-28 in behavioral studies maintained normal feeding behavior, locomotor activity, and body weight gain, suggesting an absence of gross toxicological effects at the concentrations studied.

However, it is important to contextualize these observations. Preclinical studies are typically designed to evaluate efficacy rather than to comprehensively characterize safety. Standard toxicology endpoints — including organ histopathology at multiple dose levels, reproductive toxicity, genotoxicity, and chronic exposure effects — have not been systematically evaluated for PE-22-28 in published literature. The absence of reported adverse effects in short-term behavioral experiments is not equivalent to a formal safety determination.

Theoretical Considerations

Several theoretical safety considerations arise from PE-22-28’s mechanism of action:

• TREK-1 neuroprotective role — TREK-1 channels have been shown to play a neuroprotective role during ischemic conditions. The channel opens in response to cellular stress signals (acidosis, mechanical swelling, lipid mediators released during ischemia), hyperpolarizing neurons and reducing excitotoxic calcium influx. Chronic blockade of TREK-1 could theoretically reduce this protective mechanism, though this has not been directly demonstrated with PE-22-28 in published research.
• Seizure threshold — TREK-1 channels contribute to the resting membrane potential of excitatory neurons. Blockade of background potassium conductance shifts neurons toward a more depolarized, excitable state. In principle, this could lower seizure thresholds, particularly in predisposed individuals or at high doses. TREK-1 knockout mice have not been reported to exhibit spontaneous seizures, but this remains a theoretical pharmacological consideration.
• Serotonergic interactions — PE-22-28’s enhancement of serotonergic neurotransmission raises the theoretical question of interactions with other serotonergic compounds. While no interaction studies have been published, the potential for additive serotonergic effects warrants consideration in research design.
• Long-term neurogenesis effects — While stimulation of hippocampal neurogenesis is generally viewed favorably in the context of mood and cognition research, the long-term consequences of sustained pharmacological enhancement of neurogenesis are not fully understood in any species. This is not specific to PE-22-28 but applies to any compound that promotes neural stem cell proliferation.

No Human Safety Data

PE-22-28 has not entered clinical trials in any jurisdiction. No Phase I safety/tolerability study, pharmacokinetic profiling, or dose-finding study has been conducted in human subjects. The complete absence of human safety data means that the tolerability, adverse event profile, maximum tolerated dose, drug interactions, and contraindications of PE-22-28 in humans are entirely unknown.

Summary

PE-22-28 is a synthetic heptapeptide derived from spadin, the bioactive fragment of the propeptide of sortilin (neurotensin receptor 3 precursor). Its mechanism of action — selective blockade of TREK-1 two-pore domain potassium channels — represents a mechanistically distinct approach within neuropsychiatric and neuroplasticity research. By inhibiting TREK-1 background potassium conductance, PE-22-28 increases neuronal excitability in key brain regions involved in mood regulation, serotonergic neurotransmission, and hippocampal plasticity.

In preclinical models, PE-22-28 has demonstrated antidepressant-like behavioral effects with a notably rapid onset (approximately 4 days versus 3 to 4 weeks for SSRIs in comparable rodent paradigms), upregulation of BDNF in the hippocampus, enhancement of serotonergic neurotransmission, and promotion of adult hippocampal neurogenesis. These findings have generated significant research interest in TREK-1 as a therapeutic target and in PE-22-28 as a pharmacological tool for studying the intersection of ion channel biology, neuroplasticity, and mood regulation.

However, it is essential to recognize the limitations of the current evidence base. All published data on PE-22-28 comes from preclinical models — primarily rodent behavioral and electrophysiological studies. No human clinical trials have been conducted, no formal safety assessment exists in humans, and no validated human dosing protocol has been established. The gap between preclinical promise and clinical validation remains substantial. Preclinical findings, regardless of their consistency, do not predict human outcomes with certainty, and the history of drug development contains many examples of compounds that failed to translate from animal models to clinical efficacy.

For researchers, PE-22-28 offers a selective tool for probing TREK-1 channel function across multiple experimental paradigms — from electrophysiology and neurogenesis assays to behavioral pharmacology and neurotrophic factor signaling studies. Its compact size, metabolic stability relative to full-length spadin, and demonstrated selectivity for TREK-1 make it a practical addition to the neuroscience research toolkit.

---

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Djillani et al.	2017	Original Research	Shortened spadin analogs (PE-22-28) with improved TREK-1 inhibition and antidepressant activity	PMC5601071
Mazella et al.	2010	Original Research	Spadin as a sortilin-derived TREK-1 blocker with rapid antidepressant effects	PMC2854129
Devader et al.	2015	Original Research	Spadin regulation of synaptogenesis and dendritic spine maturation in vitro and in vivo	PMC4409910
Veyssiere et al.	2014	Original Research	Retro-inverso spadin analogs with increased antidepressant effects	PMC4302242
Djillani et al.	2019	Review	TREK-1 channel role in CNS health and disease, focus on depression and neuroprotection	PMC6470294
Mazella et al.	2019	Review	Sortilin/NTSR3 involvement in depression and TREK-1 membrane expression	PMC6331531
Cong et al.	2023	Original Research	TREK-1 blockade inhibits reactive astrocyte activation via NF-κB in depression model	PMC10119044
Heurteaux et al.	2006	Original Research	TREK-1 deletion produces depression-resistant phenotype in mice	PubMed 16906152

Research Disclaimer

For laboratory and research use only. Not for human consumption.

This article is intended solely as a summary of published scientific research on PE-22-28 and TREK-1 channel biology. It does not constitute medical advice, treatment recommendations, or an endorsement of PE-22-28 for any therapeutic purpose. PE-22-28 has not been approved by the FDA or any regulatory agency for human use. No human clinical trials have been conducted with this compound. The research discussed herein is entirely preclinical (animal and cell culture studies), and results from such studies may not translate to human outcomes. Researchers should consult relevant institutional review boards and regulatory guidelines before designing studies involving this compound.

NorthPeptide supplies research-grade peptides for legitimate scientific investigation. All products are sold strictly for laboratory and research purposes. https://northpeptide.com/products/pe-22-28